FCGR3A and COVID-19: To determine associations between the CD16A polymorphism and COVID-19 disease course, we performed a retrospective analysis of 1,027 patients from a comprehensive longitudinal study designated the Immunophenotyping Assessment in a COVID-19 cohort (IMPACC) (47).